Bicycle Therapeutics $BCYC

Health Care · NASDAQ

United Kingdom
$2.90
-0.15 (-4.92%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 29, 2026, the first target we tracked for BCYC.

Bicycle Therapeutics (BCYC) is trading down at $2.90 (-4.92%) on NASDAQ, as of the latest quote. It operates in the Health Care sector.

IPO: May 23, 2019 · $14.00 offering · NASDAQ

Analyst price targets on BCYC

One firm's current price target on Bicycle Therapeutics: $10 — 245% above the current $2.9. Each is tracked to its date and scored the same way a member's call is.

1 target, newest first. Open a row for its source and scoring.

DateOct 29, 2026 FirmJefferies RatingBuy · lowers Targetat $3.82 · $10 +162% Horizonby Oct 2027 StatusOpen

Entry price $3.82, the close nearest Oct 29, 2026, when the target was reported; the target is +162% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 29, 2027.

Source Jefferies cuts Bicycle Therapeutics stock price target on trial timing Investing.com · Oct 29, 2026 · opens the publisher's site
Jefferies lowered its price target on Bicycle Therapeutics shares (NASDAQ:BCYC) to $10 from $12 while maintaining a Buy rating on the stock.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Bicycle Therapeutics revenue & net income history (FY2017–FY2025)

RevenueNet incomeNet margin (right axis, %)
$72.6M−$73.2M−$219.0MFY2017 revenue: $2.06MFY2017 net income: −$16.3M · Net margin −789.3%'17FY2018 revenue: $7.14MFY2018 net income: −$21.8M · Net margin −306.1%'18FY2019 revenue: $13.8MFY2019 net income: −$30.6M · Net margin −221.8%'19FY2020 revenue: $10.4MFY2020 net income: −$51.0M · Net margin −491.0%'20FY2021 revenue: $11.7MFY2021 net income: −$66.8M · Net margin −571.2%'21FY2022 revenue: $14.5MFY2022 net income: −$112.7M · Net margin −779.3%'22FY2023 revenue: $27.0MFY2023 net income: −$180.7M · Net margin −669.7%'23FY2024 revenue: $35.3MFY2024 net income: −$169.0M · Net margin −479.2%'24FY2025 revenue: $72.6MFY2025 net income: −$219.0M · Net margin −301.7%'25−100%−50%0%FY2017 net margin: −789.3% (off the scale, which stops at −100.0%)FY2018 net margin: −306.1% (off the scale, which stops at −100.0%)FY2019 net margin: −221.8% (off the scale, which stops at −100.0%)FY2020 net margin: −491.0% (off the scale, which stops at −100.0%)FY2021 net margin: −571.2% (off the scale, which stops at −100.0%)FY2022 net margin: −779.3% (off the scale, which stops at −100.0%)FY2023 net margin: −669.7% (off the scale, which stops at −100.0%)FY2024 net margin: −479.2% (off the scale, which stops at −100.0%)FY2025 net margin: −301.7% (off the scale, which stops at −100.0%)
Bicycle Therapeutics annual financial statements
FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$2.06M$7.14M$13.8M$10.4M$11.7M$14.5M$27.0M$35.3M$72.6M
Growth (year over year)—+246.4%+93.4%−24.7%+12.6%+23.6%+86.5%+30.8%+105.8%
Operating income−$16.2M−$21.7M−$26.3M−$52.0M−$65.6M−$116.7M−$189.9M−$209.9M−$247.1M
Operating margin−787.0%−304.7%−190.6%−500.1%−561.0%−806.6%−704.1%−595.0%−340.4%
Net income−$16.3M−$21.8M−$30.6M−$51.0M−$66.8M−$112.7M−$180.7M−$169.0M−$219.0M
Net margin−789.3%−306.1%−221.8%−491.0%−571.2%−779.3%−669.7%−479.2%−301.7%
EPS (diluted)−$48.81−$49.78−$2.77−$2.66−$2.67−$3.80−$5.08−$2.90−$3.16
Balance sheet
Cash and equivalents$67.7M$0$0$0$438.7M$339.2M$526.4M$879.5M$628.1M
Total assets—$81.6M$110.2M$161.2M$479.8M$410.6M$595.3M$956.9M$717.6M
Total liabilities—$29.3M$17.0M$65.7M$133.5M$139.8M$224.4M$163.8M$107.6M
Long-term debt———$14.5M$29.9M$30.3M$30.7M——
Shareholders' equity−$47.2M−$69.8M$93.2M$95.5M$346.3M$270.8M$370.9M$793.1M$610.0M
Cash flow
Operating cash flow−$1.42M−$26.1M−$28.6M−$17.8M−$14.8M−$86.1M−$60.6M−$164.7M−$249.7M
Capital expenditure$1.11M$1.19M$1.55M$1.20M$2.03M$19.0M$2.93M$1.24M$2.35M
Free cash flow−$2.53M−$27.3M−$30.2M−$19.0M−$16.8M−$105.1M−$63.6M−$166.0M−$252.0M

From Bicycle Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Bicycle Therapeutics in the news

Oct 29, 2026 Investing.com Jefferies cuts Bicycle Therapeutics stock price target on trial timing Target

About Bicycle Therapeutics

Headquarters
Cambridge, United Kingdom From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →